IGF::OT::IGF - PAUL C. ANDERSON MEDICINAL CHEMISTRY CONSULTANT SUPPORT SERVICES

IGF::OT::IGF - PAUL C. ANDERSON 药物化学顾问支持服务

• 批准号: 10115552
• 负责人: PAUL C ANDERSON
• 金额: $ 2.97万
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-28 至 2021-02-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10115552
• 关键词: Address; Biological; Biological Assay; Biology; Contracts; Development; Development Plans; Disease; Drug Industry; Drug Modelings; Funding; Future; Industry; Institutes; Lead; Leadership; Modeling; Neurosciences; Neurosciences Research; Peer Review; Pharmaceutical Chemistry; Pharmaceutical Preparations; Principal Investigator; Process; Program Development; Research; Research Contracts; Research Personnel; Seasons; Services; Shapes; Therapeutic; United States National Institutes of Health; Work; design; drug development; experience; indexing; innovation; nervous system disorder; programs; virtual

The NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).

代表16个NIH研究所和中心的神经科学研究的NIH蓝图宣布了神经疗法学家对神经系统疾病的有效药物的稀少挑战。为了满足这一巨大的挑战，NIH蓝图正在开创一种新的药物开发模型，该模型将行业发展专业知识与创新疾病生物学相结合，这是NIH资助的研究的实力。蓝图神经疗法网络将作为虚拟制药（http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm）运行。神经科学研究人员（主要研究人员）具有引人注目的治疗原理和药物开发项目的起始材料，将与高级，行业调查的顾问相匹配，他们将设计和指导药物开发计划。首席研究人员将进行生物活性分析和生物学工作，并将通过独立合同来确定和资助，签约研究组织（CRO）将实施所有其他药物开发活动。从事一个项目的主要调查员，顾问，NIH工作人员和CRO员工将构成领先开发团队（LDT）。